Marrone Bio Innovations, Inc. (MBII)
(Delayed Data from NSDQ)
$1.54 USD
+0.02 (1.32%)
Updated May 3, 2019 04:13 PM ET
After-Market: $1.53 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.54 USD
+0.02 (1.32%)
Updated May 3, 2019 04:13 PM ET
After-Market: $1.53 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Marrone Bio's (MBII) Earnings and Revenues Miss Estimates in Q1
by Zacks Equity Research
Marrone Bio (MBII) witnessed increased sales of row crop products in the first quarter, offset by lower sales into specialty crop markets.
Marrone Bio Innovations, Inc. (MBII) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Marrone Bio Innovations, Inc. (MBII) delivered earnings and revenue surprises of -300% and 8.29%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Marrone Bio Innovations, Inc. (MBII) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Marrone Bio Innovations, Inc. (MBII) delivered earnings and revenue surprises of 0% and 3.85%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Koppers (KOP) Q4 Earnings Beat Estimates
by Zacks Equity Research
Koppers (KOP) delivered earnings and revenue surprises of 14.93% and 1.56%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Marrone (MBII) Expands the Existing Inventory Line of Credit
by Zacks Equity Research
Marrone's (MBII) increase in the line of credit for inventory provides it with greater flexibility to support its commercial expansion in the future.
Marrone Bio (MBII) Q3 Earnings In Line, Revenues Lag Estimates
by Zacks Equity Research
Marrone Bio's (MBII) third-quarter revenues were driven by strategic focus on global expansion in the major row crops.
Marrone Bio Innovations, Inc. (MBII) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Marrone Bio Innovations, Inc. (MBII) delivered earnings and revenue surprises of 0.00% and -8.61%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Marrone Bio Innovations, Inc. (MBII) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Marrone Bio Innovations, Inc. (MBII) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Marrone Bio (MBII) Herbicides Enter Late-Stage Development
by Zacks Equity Research
Marrone's (MBII) advancements strengthen its lead position as the supplier of choice for growers looking to meet the high demand for responsibly-grown food and fiber.
Marrone (MBII) & Terramera Partner to Boost Crop Protection
by Zacks Equity Research
Marrone (MBII) and Terramera are collaborating to bring technological and biological know-how to the market to enhance crop protection and create sustainable agricultural technologies.
Marrone Bio (MBII) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Marrone Bio's (MBII) Q2 revenues were affected by severe drought in the western United States that led to reduced demand for insecticides and fungicides.
Marrone Bio Innovations, Inc. (MBII) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Marrone Bio Innovations, Inc. (MBII) delivered earnings and revenue surprises of -100.00% and -28.38%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Marrone Bio Innovations, Inc. (MBII) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
Marrone Bio Innovations, Inc. (MBII) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Marrone Bio Innovations, Inc. (MBII) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Marrone Bio Innovations, Inc. (MBII) delivered earnings and revenue surprises of 0.00% and -0.20%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Marrone Bio Innovations, Inc. (MBII) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Marrone Bio Innovations, Inc. (MBII) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Marrone Bio (MBII) Q3 Earnings In Line, Sales Trail Estimates
by Anindya Barman
Marrone Bio (MBII) posted lower year-over-year loss in Q3 on the back of a significant improvement in gross margins and lower operating expenses.
Will Marrone (MBII) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Marrone (MBII) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Lithium Help Albemarle (ALB) Beat Earnings Again in Q2?
by Anindya Barman
While Albemarle (ALB) faces certain headwinds in its Bromine and Catalysts businesses, it should gain from strength in its Lithium unit.
International Flavors (IFF) Q2 Earnings: What's in Store?
by Zacks Equity Research
International Flavors (IFF) anticipates gaining from acquired businesses as well as its multi-year productivity program. However, inflated material costs will restrain margins.
What's in the Cards for WestRock (WRK) this Earnings Season?
by Zacks Equity Research
Despite cost headwinds, favorable demand, price and mix trends across its paper and packaging businesses will aid WestRock's (WRK) earnings performance in the third quarter.
Marrone Bio (MBII) Q1 Earnings In Line, Revenues Rise Y/Y
by Zacks Equity Research
Marrone Bio (MBII) gained from manufacturing process improvement initiatives as well as favorable product mix in Q1.
Is Marrone Bio Innovations (MBII) Stock a Solid Choice Right Now?
by Zacks Equity Research
Marrone Bio Innovations (MBII) is seeing solid earnings estimate revision activity and is a great company from a Zacks Industry Rank perspective.
Marrone Bio Inks Regalia Maxx Distribution Deal With Disagro
by Zacks Equity Research
Marrone Bio's (MBII) latest move will provide growers in Central America with effective solutions for yield enhancement and disease control.
Marrone Bio's Amplitude Available for 2018 Growing Season
by Zacks Equity Research
Marrone Bio's (MBII) unique biofungicide controls soil diseases and white molds on a broad range of large acre crops, pulses, tuber and root crops.
Marrone Bio (MBII) Q3 Earnings, Revenues Miss Estimates
by Zacks Equity Research
Marrone Bio's (MBII) Q3 loss per share of 27 cents was wider than the Zacks Consensus Estimate of a loss of 24 cents.